HUE036224T2 - C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra - Google Patents

C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra

Info

Publication number
HUE036224T2
HUE036224T2 HUE14762343A HUE14762343A HUE036224T2 HU E036224 T2 HUE036224 T2 HU E036224T2 HU E14762343 A HUE14762343 A HU E14762343A HU E14762343 A HUE14762343 A HU E14762343A HU E036224 T2 HUE036224 T2 HU E036224T2
Authority
HU
Hungary
Prior art keywords
hae
prevention
treatment
hereditary angioedema
inh
Prior art date
Application number
HUE14762343A
Other languages
English (en)
Inventor
Cynthia Gallagher
Stephen Ruddy
Mark Manning
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE036224(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of HUE036224T2 publication Critical patent/HUE036224T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
HUE14762343A 2013-03-15 2014-03-17 C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra HUE036224T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
HUE036224T2 true HUE036224T2 (hu) 2018-06-28

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE17177676A HUE041837T2 (hu) 2013-03-15 2014-03-17 C1-INH készítmények és eljárások C1- észteráz inhibitor elégtelenséggel összefüggõ rendellenességek megelõzésére és kezelésére
HUE14762343A HUE036224T2 (hu) 2013-03-15 2014-03-17 C1-gátló készítmények örökletes angioödéma megelõzésében és kezelésében történõ alkalmazásra

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HUE17177676A HUE041837T2 (hu) 2013-03-15 2014-03-17 C1-INH készítmények és eljárások C1- észteráz inhibitor elégtelenséggel összefüggõ rendellenességek megelõzésére és kezelésére

Country Status (30)

Country Link
US (9) US9616111B2 (hu)
EP (3) EP3290046B1 (hu)
JP (9) JP6184581B2 (hu)
KR (4) KR102430453B1 (hu)
CN (2) CN105517559A (hu)
AU (3) AU2014232912A1 (hu)
BR (1) BR112015023207A8 (hu)
CA (2) CA3054718A1 (hu)
CY (2) CY1119419T1 (hu)
DE (1) DE202014011208U1 (hu)
DK (2) DK2968434T3 (hu)
EA (1) EA201591278A1 (hu)
ES (2) ES2639833T3 (hu)
GB (1) GB2530921B (hu)
HK (2) HK1220403A1 (hu)
HR (2) HRP20171269T1 (hu)
HU (2) HUE041837T2 (hu)
IL (2) IL241549B (hu)
LT (2) LT2968434T (hu)
ME (2) ME02865B (hu)
MX (3) MX2020004724A (hu)
NZ (2) NZ710730A (hu)
PL (2) PL3290046T3 (hu)
PT (2) PT2968434T (hu)
RS (2) RS58351B1 (hu)
SG (2) SG11201507616VA (hu)
SI (2) SI2968434T1 (hu)
TR (1) TR201900319T4 (hu)
WO (1) WO2014145519A2 (hu)
ZA (3) ZA201507604B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2968434T (pt) 2013-03-15 2017-09-18 Shire Viropharma Inc Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase
MX2016006656A (es) * 2013-11-22 2016-09-06 Shire Viropharma Inc Metodos para tratar rechazo mediado por anticuerpos en pacientes de trasplante de organos con inhibidor de c1-esterasa.
KR20170118856A (ko) * 2015-02-20 2017-10-25 체에스엘 베링 게엠베하 C1 에스테라제 억제제의 약제학적 제형
CN113999875A (zh) * 2015-05-28 2022-02-01 康奈尔大学 腺相关病毒介导的c1ei递送作为用于血管性水肿的疗法
ES2927271T3 (es) 2015-11-19 2022-11-03 Takeda Pharmaceuticals Co Inhibidor de esterasa C1 humana recombinante y usos del mismo
EP3493832A1 (en) 2016-08-05 2019-06-12 CSL Behring GmbH Pharmaceutical formulations of c1 esterase inhibitor
US20190183991A1 (en) * 2016-08-23 2019-06-20 Csl Behring Gmbh Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
BR112019023737A2 (pt) * 2017-05-16 2020-05-26 Octapharma Ag Preparação de inibidor de c1-esterase (c1-inh), kit que consiste em um primeiro receptáculo contendo a preparação de c1-inh, kit que consiste em uma seringa pré-cheia com a preparação de c1-inh, kit que consiste em um dispositivo adequado para aplicação subcutânea, tal como um injetor no corpo e uso de histidina para aumentar a biodisponibilidade de c1-inh administrado por via subcutânea
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
SG11202008078QA (en) 2018-02-28 2020-09-29 Pharming Intellectual Property B V Treatment and prevention of pre-eclampsia
AU2019288635A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
KR20210024050A (ko) 2018-06-22 2021-03-04 가부시키가이샤 준텐 바이오 감염성 면역 관용을 야기하기 위한 조성물
JPWO2019245038A1 (ja) 2018-06-22 2021-07-08 株式会社Ｊｕｎｔｅｎ Ｂｉｏ 複合状態を有する細胞混合物を用いた、免疫寛容を誘導する抗体、及び誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤及び治療法
JPWO2021124793A1 (hu) * 2019-12-16 2021-06-24
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
WO2023280981A1 (en) 2021-07-09 2023-01-12 Pharming Intellectual Property B.V. Using c1 esterase inhibitor to treat viral infection-related symptoms
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
ATE212859T1 (de) * 1993-09-01 2002-02-15 Sanquin Bloedvoorziening C1-esterasehemmer zur verringerung von myokardschäden bei akutem herzinfarkt
AU1042597A (en) 1995-12-18 1997-07-14 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
PT1252184E (pt) 2000-01-31 2008-04-15 Pharming Intellectual Pty Bv Inibidor humano c1 produzido no leite de mamíferos transgénicos
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003300781A1 (en) 2002-09-25 2004-05-04 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
ES2830499T3 (es) 2003-05-16 2021-06-03 Pharming Intellectual Property B V Inhibidor de C1 con una semivida corta para un tratamiento transitorio
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
WO2006131874A2 (en) 2005-06-06 2006-12-14 Univ Cape Town Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
CN102430117B (zh) 2005-10-21 2018-07-24 催化剂生物科学公司 抑制补体激活的修饰的蛋白酶
ATE516043T1 (de) 2005-12-21 2011-07-15 Pharming Intellectual Pty Bv Verwendung von c1-inhibitor zur prävention von ischämischen reperfusionsschäden
ES2369522T3 (es) * 2005-12-21 2011-12-01 Pharming Intellectual Property B.V. Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión.
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
CA2678001C (en) 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI629064B (zh) 2007-11-30 2018-07-11 艾伯維生物技術有限責任公司 蛋白質調配物及製造其之方法
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
CN106390117A (zh) 2009-10-16 2017-02-15 奥默罗斯公司 通过抑制masp‑2依赖性补体活化治疗弥散性血管内凝血的方法
JP6148013B2 (ja) 2010-03-05 2017-06-14 リグショスピタレト 補体活性化のキメラ抑制分子
US20130085111A1 (en) * 2010-03-18 2013-04-04 Thrombolytic Science, Llc Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
WO2013041677A1 (en) 2011-09-24 2013-03-28 Csl Behring Gmbh Combination therapy using immunoglobulin and c1-inhibitor
JP6127063B2 (ja) 2011-12-22 2017-05-10 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 中枢神経系の続発性浮腫の治療のためのｃ１インヒビターの使用
JP2015512369A (ja) 2012-03-16 2015-04-27 ベルローズ ファーマ，インコーポレーテッド Ｃ１阻害剤のポリマーコンジュゲート
EP2972375A2 (en) 2013-03-13 2016-01-20 Creatics LLC Methods and compositions for detecting pancreatic cancer
PT2968434T (pt) 2013-03-15 2017-09-18 Shire Viropharma Inc Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase

Also Published As

Publication number Publication date
US20170224788A1 (en) 2017-08-10
BR112015023207A8 (pt) 2018-01-23
JP2019073546A (ja) 2019-05-16
ZA201806793B (en) 2020-01-29
GB2530921B (en) 2017-09-20
AU2018229558B2 (en) 2020-03-05
PL2968434T3 (pl) 2018-01-31
AU2014232912A1 (en) 2015-09-03
US20180153972A1 (en) 2018-06-07
DK3290046T3 (en) 2019-03-18
US9616111B2 (en) 2017-04-11
MX2021011946A (es) 2021-11-17
ZA201507604B (en) 2018-05-30
JP6473534B2 (ja) 2019-02-20
JP2018119002A (ja) 2018-08-02
SG10201707598QA (en) 2017-10-30
AU2018229558A1 (en) 2018-10-04
AU2020203183A1 (en) 2020-06-04
JP2019073544A (ja) 2019-05-16
US20180110844A1 (en) 2018-04-26
US20160015795A1 (en) 2016-01-21
EP3508213A1 (en) 2019-07-10
IL276153B (en) 2022-06-01
LT2968434T (lt) 2017-09-25
JP6422520B2 (ja) 2018-11-14
ME03326B (me) 2019-10-20
US20190160158A1 (en) 2019-05-30
CA3054718A1 (en) 2014-09-18
IL241549B (en) 2020-08-31
JP2018119001A (ja) 2018-08-02
PT3290046T (pt) 2019-02-18
WO2014145519A3 (en) 2014-12-31
MX2015011281A (es) 2016-03-03
US11364288B2 (en) 2022-06-21
PL3290046T3 (pl) 2019-05-31
IL276153A (en) 2020-09-30
EP2968434B1 (en) 2017-06-28
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
EP3290046A1 (en) 2018-03-07
CY1121653T1 (el) 2020-07-31
MX2020004724A (es) 2022-01-18
US11534482B2 (en) 2022-12-27
GB2530921A (en) 2016-04-06
JP2017105847A (ja) 2017-06-15
EA201591278A1 (ru) 2016-03-31
SI3290046T1 (sl) 2019-04-30
CA2904543C (en) 2019-10-08
DE202014011208U1 (de) 2018-08-23
JP2021088599A (ja) 2021-06-10
HRP20171269T1 (hr) 2017-11-03
JP6877472B2 (ja) 2021-05-26
KR20210129267A (ko) 2021-10-27
US20180085441A1 (en) 2018-03-29
ZA201706929B (en) 2019-05-29
SG11201507616VA (en) 2015-10-29
KR102579789B1 (ko) 2023-09-15
CN105517559A (zh) 2016-04-20
ES2713004T3 (es) 2019-05-17
JP2016516073A (ja) 2016-06-02
RS58351B1 (sr) 2019-03-29
LT3290046T (lt) 2019-03-12
TR201900319T4 (tr) 2019-02-21
JP2018119000A (ja) 2018-08-02
KR20150135242A (ko) 2015-12-02
EP3290046B1 (en) 2019-01-02
JP2019073545A (ja) 2019-05-16
CY1119419T1 (el) 2018-03-07
CA2904543A1 (en) 2014-09-18
AU2020203183B2 (en) 2022-06-02
HK1250912B (zh) 2020-01-10
US10080788B2 (en) 2018-09-25
CN111529708A (zh) 2020-08-14
EP2968434A2 (en) 2016-01-20
HUE041837T2 (hu) 2019-05-28
GB201519921D0 (en) 2015-12-23
KR20210021146A (ko) 2021-02-24
US20200261556A1 (en) 2020-08-20
PT2968434T (pt) 2017-09-18
SI2968434T1 (sl) 2017-11-30
ES2639833T3 (es) 2017-10-30
JP6877470B2 (ja) 2021-05-26
KR102430453B1 (ko) 2022-08-05
ME02865B (me) 2018-04-20
KR20220070049A (ko) 2022-05-27
JP6473535B2 (ja) 2019-02-20
US10105423B2 (en) 2018-10-23
US20190160157A1 (en) 2019-05-30
JP6877471B2 (ja) 2021-05-26
DK2968434T3 (en) 2017-09-11
HRP20190270T1 (hr) 2019-04-05
JP6473536B2 (ja) 2019-02-20
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
EP2968434A4 (en) 2016-03-02
WO2014145519A2 (en) 2014-09-18
NZ751555A (en) 2021-07-30
JP6184581B2 (ja) 2017-08-23
HK1220403A1 (zh) 2017-05-05
BR112015023207A2 (pt) 2017-11-21

Similar Documents

Publication Publication Date Title
PT2968434T (pt) Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase
EP3052510A4 (en) Methods and compositions for treating and/or preventing mucositis
HK1215540A1 (zh) 用於治療或預防疾病的因子 蛋白、因子 蛋白及其抑制劑
EP2961420A4 (en) METHOD AND COMPOSITIONS FOR PREVENTING OR TREATING BARTH SYNDROME
HK1207288A1 (en) Itraconazole compositions and dosage forms, and methods of using the same
EP2964750A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND / OR PREVENTING TYPE-1 DIABETES
HK1207289A1 (en) Composition for prevention of vasoactivity in the treatment of blood loss and anemia
LT3097921T (lt) Kompozicijos, apimančios geraniolį ir sausą imbierą, skirtos naudoti dirgliosios žarnos sindromo gydymui
PT2862576T (pt) Microrganismos e composições que os compreendem para utilização no tratamento ou prevenção de mastite
GB201513543D0 (en) Compositions for use in the treatment of diabetes
PL3041459T3 (pl) Kompozycje przydatne w zapobieganiu lub leczeniu raka skóry
AU2013904048A0 (en) Compositions and methods for the prevention and/or treatment of neurogenic inflammation and/or infla
TH1401007825A (th) องค์ประกอบที่มีน้ำชาสำหรับการป้องกันการเปลี่ยนตามวัยของผิวหนัง